April 1, 2007 -- For the week, the Centient Biotech 200™ fell 18 points to 3879, a loss of about a half of a percentage point. Breadth was in line with the small decline. The Monday edition of Barron’s carries a review of Alzheimer’s drugs, with particular attention to Wyeth, which has 11 AD drugs in development. In the IPO sector, device maker SenoRx made its debut during the last week. On the CBT 200™ list, Dendreon was the clear winner with a spectacular 189% gain, after receiving a recommendation for cancer drug Provenge; Biosite moved up 52% on a buyout offer; Targeted Genetics roared 44% higher following a positive Q4 report; Cell Genesys, riding the coattails of Dendreon, was up 40%; and BioSante had a 28% gain after receiving a $7 million milestone. More details...
